145 related articles for article (PubMed ID: 37838145)
1. A shift of paradigm: From avoiding nanoparticular complement activation in the field of nanomedicines to its exploitation in the context of vaccine development.
Barbey C; Wolf H; Wagner R; Pauly D; Breunig M
Eur J Pharm Biopharm; 2023 Dec; 193():119-128. PubMed ID: 37838145
[TBL] [Abstract][Full Text] [Related]
2. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals.
Szebeni J
Mol Immunol; 2014 Oct; 61(2):163-73. PubMed ID: 25124145
[TBL] [Abstract][Full Text] [Related]
3. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization.
Mészáros T; Kozma GT; Shimizu T; Miyahara K; Turjeman K; Ishida T; Barenholz Y; Urbanics R; Szebeni J
Int J Nanomedicine; 2018; 13():6345-6357. PubMed ID: 30349254
[TBL] [Abstract][Full Text] [Related]
4. Combating Complement's Deleterious Effects on Nanomedicine by Conjugating Complement Regulatory Proteins to Nanoparticles.
Wang Z; Hood ED; Nong J; Ding J; Marcos-Contreras OA; Glassman PM; Rubey KM; Zaleski M; Espy CL; Gullipali D; Miwa T; Muzykantov VR; Song WC; Myerson JW; Brenner JS
Adv Mater; 2022 Feb; 34(8):e2107070. PubMed ID: 34910334
[TBL] [Abstract][Full Text] [Related]
5. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
Szebeni J; Muggia F; Gabizon A; Barenholz Y
Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
[TBL] [Abstract][Full Text] [Related]
6. CH(50): a revisited hemolytic complement consumption assay for evaluation of nanoparticles and blood plasma protein interaction.
Meerasa A; Huang JG; Gu FX
Curr Drug Deliv; 2011 May; 8(3):290-8. PubMed ID: 21291380
[TBL] [Abstract][Full Text] [Related]
7. Exploiting lymphatic transport and complement activation in nanoparticle vaccines.
Reddy ST; van der Vlies AJ; Simeoni E; Angeli V; Randolph GJ; O'Neil CP; Lee LK; Swartz MA; Hubbell JA
Nat Biotechnol; 2007 Oct; 25(10):1159-64. PubMed ID: 17873867
[TBL] [Abstract][Full Text] [Related]
8. Engineering Strategies for Lymph Node Targeted Immune Activation.
Chen Y; De Koker S; De Geest BG
Acc Chem Res; 2020 Oct; 53(10):2055-2067. PubMed ID: 32910636
[TBL] [Abstract][Full Text] [Related]
9. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model.
Jackman JA; Mészáros T; Fülöp T; Urbanics R; Szebeni J; Cho NJ
Nanomedicine; 2016 May; 12(4):933-943. PubMed ID: 26767512
[TBL] [Abstract][Full Text] [Related]
10. Amino-Modified Polymer Nanoparticles as Adjuvants to Activate the Complement System and to Improve Vaccine Efficacy in Vivo.
Pan Y; Qi Y; Shao N; Tadle AC; Huang Y
Biomacromolecules; 2019 Sep; 20(9):3575-3583. PubMed ID: 31415161
[TBL] [Abstract][Full Text] [Related]
11. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor.
Dézsi L; Mészáros T; Kozma G; H-Velkei M; Oláh CZ; Szabó M; Patkó Z; Fülöp T; Hennies M; Szebeni M; Barta BA; Merkely B; Radovits T; Szebeni J
Geroscience; 2022 Apr; 44(2):597-618. PubMed ID: 35146583
[TBL] [Abstract][Full Text] [Related]
12. Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth.
Moghimi SM
J Control Release; 2014 Sep; 190():556-62. PubMed ID: 24746624
[TBL] [Abstract][Full Text] [Related]
13. Protein corona-mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses.
Shen L; Tenzer S; Storck W; Hobernik D; Raker VK; Fischer K; Decker S; Dzionek A; Krauthäuser S; Diken M; Nikolaev A; Maxeiner J; Schuster P; Kappel C; Verschoor A; Schild H; Grabbe S; Bros M
J Allergy Clin Immunol; 2018 Nov; 142(5):1558-1570. PubMed ID: 29382591
[TBL] [Abstract][Full Text] [Related]
14. Development of a Sensitive Assay to Screen Nanoparticles
Maisha N; Coombs T; Lavik E
ACS Biomater Sci Eng; 2020 Sep; 6(9):4903-4915. PubMed ID: 33313396
[TBL] [Abstract][Full Text] [Related]
15. Complement system and the brain: selected pathologies and avenues toward engineering of neurological nanomedicines.
Lettiero B; Andersen AJ; Hunter AC; Moghimi SM
J Control Release; 2012 Jul; 161(2):283-9. PubMed ID: 22094105
[TBL] [Abstract][Full Text] [Related]
16. Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: Correlation with physicochemical features and clinical information.
Fülöp T; Nemes R; Mészáros T; Urbanics R; Kok RJ; Jackman JA; Cho NJ; Storm G; Szebeni J
J Control Release; 2018 Jan; 270():268-274. PubMed ID: 29203414
[TBL] [Abstract][Full Text] [Related]
17. Cloaking Silica Nanoparticles with Functional Protein Coatings for Reduced Complement Activation and Cellular Uptake.
Park JH; Jackman JA; Ferhan AR; Belling JN; Mokrzecka N; Weiss PS; Cho NJ
ACS Nano; 2020 Sep; 14(9):11950-11961. PubMed ID: 32845615
[TBL] [Abstract][Full Text] [Related]
18. Tailored Polymers with Complement Activation Ability To Improve Antitumor Immunity.
Li C; Lu Y; Chen Q; Hu H; Zhao X; Qiao M; Chen D
Mol Pharm; 2019 Jun; 16(6):2648-2660. PubMed ID: 31046290
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle physicochemical properties determine the activation of intracellular complement.
Ilinskaya AN; Shah A; Enciso AE; Chan KC; Kaczmarczyk JA; Blonder J; Simanek EE; Dobrovolskaia MA
Nanomedicine; 2019 Apr; 17():266-275. PubMed ID: 30794962
[TBL] [Abstract][Full Text] [Related]
20. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
